Fred Hutch Cancer Center | Association Partnerships

This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.

This segment focuses on the key considerations for diagnosing cGvHD and the initial treatment approaches, including the use of corticosteroids and combination therapies. The discussion covers factors that guide the decision-making process, such as organ involvement, severity of symptoms, and response to initial therapy.

David Zhen, MD, provides advice to oncologists treating patients with upper gastric cancer and offers closing thoughts on the future treatment landscape, highlighting challenges and unmet needs.

Turning the focus to ongoing research, an expert on upper gastric cancer discusses novel targets being investigated in clinical trials and the evolving treatment landscape.

A medical oncologist discusses the treatment of patients with gastric adenocarcinoma who have progressed following treatment with immunotherapy.

David Zhen, MD, provides clinical insights on the management of adverse events stemming from immunotherapy in patients with upper gastric cancer.

Expert perspectives on the role of immunotherapies in upper gastrointestinal cancers, highlighting the CheckMate 649 study investigating frontline nivolumab plus chemotherapy.

A medical oncologist reviews the available frontline treatment options for patients with gastric adenocarcinoma.

David Zhen, MD, reviews the profile of a 60-year-old man with stage IV gastric adenocarcinoma and offers his initial impressions on the case.

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Chronic GVHD specialists share commentary on long-term effects of graft versus host disease and therapies for the condition.

The clinical trial of a novel agent, axatilimab, is reviewed and analyzed.

Clinical experiences with belusmosudil are shared among the panel.

Corey Cutler explains the ROCKstar clinical trial of belumosudil for steroid-refractory chronic GVHD.

Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.

The panel discusses the iNTERGRATE trial of ibrutinib in combination with prednisone as frontline therapy for chronic GVHD.

Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.

Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.

The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.

The group discusses treatment goals and patient education for chronic GVHD.

Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.

Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.

Corey Cutler details the NIH Clinical Scoring of Organ System for chronic GHVD symptoms.

Colleen Danielson, NP, walks through how chronic GVHD symptoms are assessed.

Discussing findings from a phase 1/2 study, Sarah P. Psutka MD, looks at the use of acupuncture for patients with non muscle-invasive bladder cancer prior to induction of their BCG treatment.

The panelists share their insights on the identification of patients at high risk for GVHD.

Dr Chen presents statistics on the incidence of chronic graft versus host disease.

Colleen Danielson, NP shares the signs and symptoms she commonly sees in patients with graft versus host disease.

Yi-Bin Chen leads the panel in a review of various GVHD prophylaxis regimens.

Catherine Lee explains risk factors that may contribute to the likelihood of a patient developing graft versus host disease.